Vaccinex, Inc. (VCNX)
NASDAQ: VCNX · Real-Time Price · USD
3.240
+0.290 (9.83%)
Nov 4, 2024, 4:00 PM EST - Market closed
Vaccinex Employees
As of December 31, 2023, Vaccinex had 40 total employees, including 37 full-time and 3 part-time employees. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
$8,900
Profits / Employee
-$443,925
Market Cap
8.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareMax | 1,450 |
Syra Health | 162 |
Ontrak | 104 |
Viracta Therapeutics | 40 |
Genprex | 26 |
Pulmatrix | 22 |
Coeptis Therapeutics Holdings | 7 |
Alzamend Neuro | 7 |
VCNX News
- 4 days ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 6 weeks ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire
- 2 months ago - Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership - GlobeNewsWire
- 3 months ago - Vaccinex stock tanks 40% despite positive Alzheimer's study update - Invezz
- 5 months ago - Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease - GlobeNewsWire
- 6 months ago - Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Vaccinex Reports 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire